| 1.08 Real-Time Quote | +0.04 / +3.85%Today’s Change | 0.99 Today|||52-Week Range 5.10 | -62.11% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $190.2M |
Company Description
Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company, which discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The company's product candidates is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines. Dynavax Technologies was founded on August 29, 1996 by Dennis A. Carson, Eyal Raz and Lawrence M. Lichtenstein and is headquartered in Berkeley, CA.
Employees

Shareholders
| Individual stakeholders | 8.79% |
| Mutual fund holders | 48.76% |
| Other institutional | 35.22% |
Top Executives
| Eddie J. Gray, MBA | Chief Executive Officer & Director |
| David F. Novack, MBA | Senior Vice President-Operations & Quality |
| Jennifer Lew, CPA | Chief Financial Officer, CAO & Vice President |
| Robert L. Coffman, PhD | Chief Scientific Officer & Vice President |
| William L. Heyward, MD | Vice President-Clinical Development |